A new study published recently has found an antibody capable of blocking a protein that helps cancer cells evade detection by the immune system. The paper suggests that antibody MPDL3280A blocks protein PD-L1, which was allowing cancer cells to avoid destruction by the immune system.
68 patients with advanced bladder cancer who had failed other treatments participated in the research program. 30 of those patients had tumors which contained the PD-L1 protein. They were given a drug containing the MPDL3280A antibody. Within twelve weeks of treatment, of those 30, 52% saw their tumors shrink in size. In two of the patients, the cancer was completely eradicated! Of the remaining 38 patients who did not have the PD-L1 protein in their tumors, 11% still saw some positive effect from the drug.
The antibody has received “breakthrough therapy” designation status by the FDA, which speeds up it’s approval process.
The American Cancer Society estimates that 74,690 cases of bladder cancer will be diagnosed in 2014, with 15,580 deaths from the disease this year. The research is very exciting because bladder cancer usually carries a very poor prognosis.